---
title: 'Artificial intelligence for diagnosis and Gleason grading of prostate cancer:
  the PANDA challenge'
authors:
- Wouter Bulten
- Kimmo Kartasalo
- Po-Hsuan Cameron Chen
- Peter Ström
- Hans Pinckaers
- Kunal Nagpal
- Yuannan Cai
- David F. Steiner
- Hester van Boven
- Robert Vink
- Christina Hulsbergen-van de Kaa
- Jeroen van der Laak
- Mahul B. Amin
- Andrew J. Evans
- Theodorus van der Kwast
- Robert Allan
- Peter A. Humphrey
- Henrik Grönberg
- Hemamali Samaratunga
- Brett Delahunt
- Toyonori Tsuzuki
- Tomi Häkkinen
- Lars Egevad
- Maggie Demkin
- Sohier Dane
- Fraser Tan
- Masi Valkonen
- Greg S. Corrado
- Lily Peng
- Craig H. Mermel
- Pekka Ruusuvuori
- Geert Litjens
- Martin Eklund
- Américo Brilhante
- Aslı Çakır
- Xavier Farré
- Katerina Geronatsiou
- Vincent Molinié
- Guilherme Pereira
- Paromita Roy
- Günter Saile
- Paulo G. O. Salles
- Ewout Schaafsma
- Joëlle Tschui
- Jorge Billoch-Lima
- Emíio M. Pereira
- Ming Zhou
- Shujun He
- Sejun Song
- Qing Sun
- Hiroshi Yoshihara
- Taiki Yamaguchi
- Kosaku Ono
- Tao Shen
- Jianyi Ji
- Arnaud Roussel
- Kairong Zhou
- Tianrui Chai
- Nina Weng
- Dmitry Grechka
- Maxim V. Shugaev
- Raphael Kiminya
- Vassili Kovalev
- Dmitry Voynov
- Valery Malyshev
- Elizabeth Lapo
- Manuel Campos
- Noriaki Ota
- Shinsuke Yamaoka
- Yusuke Fujimoto
- Kentaro Yoshioka
- Joni Juvonen
- Mikko Tukiainen
- Antti Karlsson
- Rui Guo
- Chia-Lun Hsieh
- Igor Zubarev
- Habib S. T. Bukhar
- Wenyuan Li
- Jiayun Li
- William Speier
- Corey Arnold
- Kyungdoc Kim
- Byeonguk Bae
- Yeong Won Kim
- Hong-Seok Lee
- Jeonghyuk Park
- the PANDA challenge consortium
date: '2022-01-01'
publishDate: '2024-07-30T09:27:10.193679Z'
publication_types:
- article-journal
publication: '*Nat Med*'
doi: 10.1038/s41591-021-01620-2
abstract: Artificial intelligence (AI) has shown promise for diagnosing prostate cancer
  in biopsies. However, results have been limited to individual studies, lacking validation
  in multinational settings. Competitions have been shown to be accelerators for medical
  imaging innovations, but their impact is hindered by lack of reproducibility and
  independent validation. With this in mind, we organized the PANDA challenge--the
  largest histopathology competition to date, joined by 1,290 developers--to catalyze
  development of reproducible AI algorithms for Gleason grading using 10,616 digitized
  prostate biopsies. We validated that a diverse set of submitted algorithms reached
  pathologist-level performance on independent cross-continental cohorts, fully blinded
  to the algorithm developers. On United States and European external validation sets,
  the algorithms achieved agreements of 0.862 (quadratically weighted κ, 95% confidence
  interval (CI), 0.840-0.884) and 0.868 (95% CI, 0.835-0.900) with expert uropathologists.
  Successful generalization across different patient populations, laboratories and
  reference standards, achieved by a variety of algorithmic approaches, warrants evaluating
  AI-based Gleason grading in prospective clinical trials.
links:
- name: URL
  url: https://doi.org/10.1038/s41591-021-01620-2
---
